{"schema_version":"secwatch.filing_event.v1","accession":"0001787306-23-000122","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2023-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.448292+00:00","generated_at":"2026-06-08T22:40:14.321184+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arcutis reports Q3 2023 total revenue of $38.1M, ZORYVE sales up 70% QoQ to $8.1M","bullets":["Net loss $44.8M ($0.73 EPS) vs loss $107.7M ($1.89 EPS) in Q3 2022; R&D expense down to $26.2M.","ZORYVE plaque psoriasis prescriptions over 110k from nearly 9k prescribers; FDA approved expanded indication to children ages 6+.","sNDA submitted for roflumilast cream 0.15% for atopic dermatitis ages 6+; potential approval Q3 2024.","Completed $100M public offering in Oct 2023; amended SLR debt facility removing market cap covenant, requires $31M additional capital by Apr 2024.","Appointed Todd Edwards CCO and John Smither interim CFO; Huadong collaboration upfront $30M."],"urls":{"canonical":"https://secwatch.observer/filing/0001787306-23-000122","json":"https://secwatch.observer/filing/0001787306-23-000122.json","markdown":"https://secwatch.observer/filing/0001787306-23-000122.md","text":"https://secwatch.observer/filing/0001787306-23-000122.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000122/0001787306-23-000122-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000122/arqt-20231103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T22:40:14.321184+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2dcdbd0ebb7e8a20e31e76592d1b835b49740a44","claim":"Arcutis Biotherapeutics, Inc. reported quarter ended September 30, 2023 results: revenue net product revenues for ZORYVE (roflumilast) cream 0.3% were $8.1 million.","evidence_excerpt":"2023 Financial Results and Provides Business Update • Achieved total revenues of $38.1 million in the third quarter of 2023. Net product revenues for ZORYVE® (roflumilast) cream 0.3% were $8.1 million, a 70% increase compared to the second quarter of 2023, driven by sequential improvement in gross-to-net (GTN) down to the low 70 percent range, as well as","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000122/0001787306-23-000122-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2023"},{"label":"Revenue","value":"net product revenues for ZORYVE (roflumilast) cream 0.3% were $8.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}